Registe-se para criar alertas sobre instrumentos,
eventos económicos e conteúdo por autores seguidos
Registe-se grátis Já tem uma conta? Iniciar
Cotações
Todos os tipos
- Todos os tipos
- Índices
- Ações
- ETFs
- Fundos
- Matérias-primas
- Moedas
- Cripto
- Obrigações
- Certificados
Por favor, tente outra pesquisa
Desbloqueie Dados Premium: Poupe até 50% na InvestingPro OBTER OFERTA
Ubs (lux) Equity Fund - Biotech (usd) Q-acc (0P0000XHD3)
Adicionar/Remover de uma carteira
Adicionar a Watchlist
328,670
+11,320
+3,57%
Tipo:
Fundo
Mercado:
Luxemburgo
Emissor:
UBS Fund Management (Luxembourg) S.A.
ISIN:
LU0400035332
Classe de Ativo:
Açao
- Classificação da Morningstar:
- Ativos Totais: 498,51M
UBS Lux Equity Fund - Biotech USD Q-acc
328,670
+11,320
+3,57%
Ubs (lux) Equity Fund - Biotech (usd) Q-acc - Vista Geral
Nesta página encontrará um perfil aprofundado de Ubs (lux) Equity Fund - Biotech (usd) Q-acc. Fique a saber mais sobre as pessoas-chave, o total de ativos, a estratégia de investimento e a informação de contacto de 0P0000XHD3, e mais.
Estratégia de investimento
O fundo investe principalmente a nível global em ações de empresas com uma ligação ao sector da biotecnologia. Ao trabalhar com base em análises bem fundamentadas por parte dos nossos especialistas de investimento em todo o mundo, o gestor do fundo combina ações cuidadosamente selecionadas de várias empresas e segmentos com o objetivo de explorar interessantes oportunidades de ganhos enquanto mantém o nível de risco sob controlo. Em princípio, os investidores podem solicitar à sociedade gestora para resgatar as suas unidades em qualquer dia útil bancário normal no Luxemburgo. O rendimento desta classe de unidades é reinvestido.
Informações de Contacto
Endereço
33A, avenue J.-F. Kennedy, L-1855 Luxembourg
Luxembourg, L-1855
Luxembourg
Luxembourg, L-1855
Luxembourg
Telefone
+352-441 0101
Principais Executivos
| Nome | Título | Desde | Até |
|---|---|---|---|
| Sara Cotter | - | 2022 | Agora |
| Matthew Konosky | - | 2017 | Agora |
| Biografia | Matthew Konosky is the Lead Healthcare Portfolio Manager and a Senior Investment Analyst on UBS Asset Management's US Intrinsic Value Equity Team. In his portfolio manager role, Matthew is Lead Portfolio Manager for the Global Healthcare Lux Fund as well as Deputy Portfolio Manager for the Global Biotech Lux Fund. Analyst responsibilities include fundamental company and industry-level research and development of company earnings models for the global pharmaceuticals and health care services sectors. Prior to joining the firm in 2006, Matthew worked as health care services analyst at Sanford C. Bernstein in New York and as a senior consultant at Mars & Co. serving several Fortune 500 health care clients. Matthew has also served as a member of the MIT Educational Counsel since 1997. | ||
| Florian Töpfl | - | 2019 | 2023 |
| Nathalie Lötscher Petrus | - | 2006 | 2022 |
| Christian Suter | - | 2012 | 2019 |
| Biografia | Christian Suter is an Equity Specialist, based in Zurich. He works closely together with the equity investment teams of UBS Asset Management and is responsible for presenting equity strategies to clients, prospects and consultants, primarily focusing on our Swiss, Biotech and Healthcare strategies. Further Christian is the deputy portfolio manager for the Swiss High Dividend and Swiss Income strategies and acts as a member of the portfolio construction team for Swiss Equities. In addition Christian covers Swiss Small and Mid Cap Industrials as well as the Biotech sector as an analyst. In 2009, Christian joined UBS within the graduate training program for the second time, after he made his first experiences at UBS before University in UBS WM&SB and UBS Investment Bank. | ||
| André Leue | - | 2016 | 2017 |
| Biografia | André Leue is a Senior Investment Analyst. He is responsible for industry and company research, qualitative assessment and quantitative financial modelling within the Healthcare sector. André is Deputy Portfolio Manager for the UBS (Lux) Equity Fund – Biotech. André joined UBS Asset Management in February 2010. Prior to this he was head of the Healthcare team at DEKA Investment. As the Lead Portfolio Manager he was responsible for a Healthcare fund and a Biotech fund with combined assets under management of around USD 2bn. Other previous roles included senior financial analyst at Sal. Oppenheim Jr. & Cie and financial auditor at KPMG International. | ||
| Scott Wilkin | - | 2016 | 2016 |
| Biografia | Scott is the Head of the Global Intrinsic Value Equity team and co-PM for our Global equity portfolios. He is also Director of Research (DOR); responsible for managing the 13-member analyst team and driving research quality standards across the Global Intrinsic Value platform. In 2012, Scott was promoted to the position of DOR for the US Intrinsic Value equity team. In this role, Scott managed a team of six sector-based analysts and lead company and industry-level research. Scott was also the lead portfolio manager of the Intrinsic Value equity team's Global Healthcare and UBS Healthcare Long/Short strategies. Prior to being named DOR and portfolio manager, Scott was a Senior Investment Analyst and Sector Head for the health care analyst team. His responsibilities included fundamental company and industry-level research. | ||
| Sara Cotter | - | 2015 | 2016 |
| Angus Muirhead | - | 2012 | 2015 |
Escreva o que você pensa sobre Ubs (lux) Equity Fund - Biotech (usd) Q-acc
Tem certeza que deseja eliminar este gráfico?
Eliminar Cancelar
Substituir o gráfico anexado por um novo gráfico?
Substituir Cancelar
Diretrizes para Comentários
Anexar um gráfico a um comentário
Confirmar Bloqueio
Quer mesmo bloquear %USER_NAME%?
Se o fizer, não poderá consultar as mensagens de %USER_NAME% e vice versa em Investing.com.
Adicionou %USER_NAME% com sucesso à sua Lista de Bloqueios
Uma vez que acabou de desbloquear esta pessoa, deve aguardar 48 horas antes de bloqueá-la novamente.
Denunciar este comentário
Diga-nos o que achou deste comentário
Comentário denunciado
Obrigado!
Seu comentário foi enviado aos moderadores para revisão